| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
| Targets |
DNA methyltransferases (DNMTs); RNA metabolism pathways. N4-Methylcytidine is a cytidine nucleoside analog that inhibits DNA methyltransferases. Cytidine analogs have a mechanism of inhibiting DNA methyltransferase and have potential anti-metabolic and anti-tumor activities. The compound also plays roles in RNA modification, affecting gene expression regulation and RNA stability.
|
|---|---|
| ln Vitro |
N4-Methylcytidine demonstrates activity as a cytidine nucleoside analog in cellular assays. It inhibits DNA methyltransferases and has potential anti-metabolic and anti-tumor activities. It is used as a research tool in epigenetic studies. Detailed IC50 values have not been disclosed.
|
| ln Vivo |
In vivo activity of N4-Methylcytidine has not been extensively characterized. As a cytidine analog, it would be expected to have anti-tumor activity in animal models. The compound is primarily used in research on epigenetic regulation, DNA methylation dynamics, and tumor-associated metabolic reprogramming.
|
| Enzyme Assay |
In vitro enzyme assays for DNA methyltransferase inhibition are performed using recombinant DNMT enzymes and DNA substrates in the presence of S-adenosylmethionine (SAM). N4-Methylcytidine is incubated at varying concentrations with the enzyme and substrate. Methylation is detected by radioactivity or immunoassay. IC50 values are calculated from dose-response curves.
|
| Cell Assay |
Cells (e.g., cancer cell lines) are cultured and treated with N4-Methylcytidine at concentrations typically ranging from 1–100 μM for 24–72 hours. DNA methylation levels are assessed by methylation-specific PCR or bisulfite sequencing. DNMT inhibition is assessed by measuring global DNA methylation or specific gene methylation. Cell viability and proliferation are evaluated by standard assays.
|
| Animal Protocol |
In vivo animal studies for N4-Methylcytidine have not been reported in publicly available literature. The compound is primarily used as an in vitro research tool for epigenetic studies. Future studies in animal models of cancer would be needed to evaluate in vivo efficacy.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for N4-Methylcytidine have not been published. The compound has a molecular weight of 257.24 and formula C10H15N3O5. As a cytidine analog, it is expected to be taken up by cells via nucleoside transporters. In vivo PK parameters such as half-life, bioavailability, and tissue distribution have not been characterized.
|
| Toxicity/Toxicokinetics |
Toxicology data for N4-Methylcytidine have not been published. The compound is for research use only and not approved for human therapeutic applications. No systematic toxicological evaluation has been performed. Standard safety precautions for handling nucleoside analogs should be observed.
|
| References | |
| Additional Infomation |
N4-methylcytidine is a pyrimidine nucleoside.
N4-Methylcytidine (CAS: 10578-79-7, molecular formula C10H15N3O5, molecular weight 257.24) is a cytidine nucleoside analog and RNA modification. It inhibits DNA methyltransferases and has potential anti-metabolic and anti-tumor activities. It is used in research on epigenetic regulation and DNA methylation dynamics. It is not in clinical trials and has no regulatory approval. |
| Molecular Formula |
C10H15N3O5
|
|---|---|
| Molecular Weight |
257.24
|
| Exact Mass |
257.101
|
| CAS # |
10578-79-7
|
| PubChem CID |
101436
|
| Appearance |
White to off-white solid powder
|
| Density |
1.69g/cm3
|
| Boiling Point |
504.2ºC at 760mmHg
|
| Flash Point |
258.7ºC
|
| Vapour Pressure |
2.82E-12mmHg at 25°C
|
| Index of Refraction |
1.694
|
| LogP |
-1.7
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
18
|
| Complexity |
397
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
CNC1=NC(=O)N(C=C1)[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O
|
| InChi Key |
LZCNWAXLJWBRJE-ZOQUXTDFSA-N
|
| InChi Code |
InChI=1S/C10H15N3O5/c1-11-6-2-3-13(10(17)12-6)9-8(16)7(15)5(4-14)18-9/h2-3,5,7-9,14-16H,4H2,1H3,(H,11,12,17)/t5-,7-,8-,9-/m1/s1
|
| Chemical Name |
1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-4-(methylamino)pyrimidin-2-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~50 mg/mL (~194.4 mM; with ultrasonication)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (9.72 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), Clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 400 μL of PEG300 and mix well; then add 50 μL of Tween-80 and mix well; finally add 450 μL of physiological saline and adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (9.72 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 900 μL of 20% SBE-β-CD saline and mix well. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 2.5 mg/mL (9.72 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 900 μL of corn oil and mix well. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.8874 mL | 19.4371 mL | 38.8742 mL | |
| 5 mM | 0.7775 mL | 3.8874 mL | 7.7748 mL | |
| 10 mM | 0.3887 mL | 1.9437 mL | 3.8874 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
